דילוג לתוכן הראשי
xMedica

NCT07784725ClinicalTrials.gov

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity Without Type 2 Diabetes Mellitus (SELENE 1)

מגייסמקבל משתתפים כעת, לפי רשומת המרשם.
יצירת קשר עם המחקר

בקצרה

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

שלב 3דרושים 2,500 משתתפים220 אתרים16 מדינות

קטגוריות

רשום במרשם אחד

מחקר יחיד יכול להיות רשום בכמה מרשמים. אנו מציגים אותו פעם אחת ומקשרים לכל רשומה שברשותנו.

מידע הניסוי מוצג כפי שפורסם על ידי המרשם, בשפת המקור שלו.

מתעניינים במחקר הזה?

התחברות או צרו חשבון כדי לרשום את התעניינותכם ולעקוב אחר המחקר הזה.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 6 days after the recorded start)First posted 2026-08-25; recorded start 2026-08-19
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 212 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 2,500 participants (target), run at 220 sites, across 16 countries.

How this score is built
  • Enrolment34/40

    2,500 participants (target)

  • Site count25/25

    212 sites

  • Country count15/15

    16 countries

  • Planned duration8/10

    Planned over about 34 months

  • Sponsor scale10/10

    AstraZeneca has led 1,017 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

תקציר

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

This is a Phase III, global, randomised, parallel-group, double-blind, multicentre study to assess the efficacy and safety of AZD6234 compared with placebo, administered SC once weekly in adults with obesity or overweight with at least one weight-related comorbidity without T2DM. Eligible participants will be randomized to either receive AZD6234 or matching placebo respectively.

מצבים רפואיים

  • Obesity or Overweight

זכאות

זכאות
מיןהכול
גילאים18 Years – ללא מקסימום
מתנדבים בריאיםלא

זכאות כפי שנכתבה במרשם

Inclusion Criteria: * Males \& females (inclusive of all gender identities) age ≥18 years * BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with at least one of the following weight related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, heart failure, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, osteoarthritis of the knee, or stress urinary incontinence * Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation * History of at least one self-reported unsuccessful attempt to lose body weight in their lifetime Exclusion Criteria: * Obesity primarily caused by other endocrine disorders * History of Type 1 or Type 2 Diabetes Mellitus, HbA1c ≥6.5% (48 mmol/mol), and/or treatment with glucose-lowering agent(s) within 3 months prior to Screening * Significant hepatobiliary disease and/or any of the following results at Screening: * ALT ≥ 3.0 × ULN * AST ≥ 3.0 × ULN * TBL \> 1.5 × ULN (except for cases of known Gilbert's Syndrome) * Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation.

זכאות במשפטים פשוטים

הקריטריונים של רשומה זו טרם פורקו למשפטים נפרדים. טקסט המרשם שלמעלה שלם והוא הגרסה המחייבת.

תכנון המחקר

תכנון המחקר
סוג המחקרהתערבותי
שלבשלב 3
הקצאהאקראי
מודל ההתערבותPARALLEL
מטרה ראשיתTREATMENT
הסתרהQUADRUPLE (4)
גיוסדרושים 2,500 משתתפים

נותן חסות ושותפים

  • AstraZeneca נותן חסות

זרועות והתערבויות

  • AZD6234 Dose 1EXPERIMENTAL

    AZD6234 Dose 1

  • AZD6234 Dose 2EXPERIMENTAL

    AZD6234 Dose 2

  • PlaceboPLACEBO_COMPARATOR

    Matching placebo

התערבויות

  • תרופה Lenbelintide

    IMP injected subcutaneously, once a week. Unit dose strength as per CSP.

  • תרופה Placebo

    Placebo matching IMP dose injected subcutaneously, once a week.

מדדי תוצאה

  1. מדד תוצאה ראשוני

    Percent change in body weight from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo in percent body weight change

    מסגרת זמן 68 weeks

  2. מדד תוצאה משני

    Absolute change in weight (kg) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on absolute change in weight

    מסגרת זמן 68 weeks

  3. מדד תוצאה משני

    Achievement of at least 5 % body weight loss from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 5%

    מסגרת זמן 68 weeks

  4. מדד תוצאה משני

    Achievement of at least 10% body weight loss from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 10%

    מסגרת זמן 68 weeks

  5. מדד תוצאה משני

    Change in waist circumference (cm) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on waist circumference change

    מסגרת זמן 68 weeks

  6. מדד תוצאה משני

    Percent change in triglycerides from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on triglycerides percent change

    מסגרת זמן 68 weeks

  7. מדד תוצאה משני

    Change in systolic blood pressure (mmHg) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on systolic blood pressure change

    מסגרת זמן 68 weeks

  8. מדד תוצאה משני

    Percent change in fat mass from baseline at 68 weeks of treatment measured by DXA in the DXA Sub-Study subset

    Body Composition Sub-study: To evaluate the effect of AZD6234 as compared to placebo on body composition change in the DXA subset of participants

    מסגרת זמן 68 weeks

תאריכים

תאריכים
תאריך התחלה19 באוגוסט 2026 (בפועל)
סיום ראשוני11 באוגוסט 2028 (משוער)
סיום21 במאי 2029 (משוער)
פורסם לראשונה25 באוגוסט 2026 (בפועל)
עודכן לאחרונה30 באוקטובר 2026
התוצאות פורסמולא צוין ברשומת המרשם
המצב אומת לאחרונהאוקטובר 2026

בפועל פירושו שהאירוע התרחש. משוער פירושו שנותן החסות צופה אותו. שתי המשמעויות שונות זו מזו.

מיקומים

76 אתרים מגייסים

Argentina

Argentina
מתקןעירמדינה או אזורמצב
Research SiteBuenos Airesמגייס
Research SiteBuenos Airesמגייס
Research SiteCiudad de Buenos Airesמגייס
Research SiteMendozaמגייס
Research SiteRamos Mejíaטרם מגייס
Research SiteRosarioמגייס
Research SiteSan Nicolásטרם מגייס

Australia

Australia
מתקןעירמדינה או אזורמצב
Research SiteBotanyמגייס
Research SiteCamberwellמגייס
Research SiteCharlestownמגייס
Research SiteSt Albansמגייס
Research SiteSt Leonardsמגייס
Research SiteWaitaraמגייס

Brazil

Brazil
מתקןעירמדינה או אזורמצב
Research SiteBelo Horizonteטרם מגייס
Research SiteBrasíliaטרם מגייס
Research SiteCampinasטרם מגייס
Research SiteCampinasטרם מגייס
Research SiteCuritibaבוטל
Research SiteCuritibaטרם מגייס
Research SiteCuritibaטרם מגייס
Research SiteNatalטרם מגייס
Research SitePorto Alegreטרם מגייס
Research SiteRio de Janeiroטרם מגייס
Research SiteSão José dos Camposטרם מגייס
Research SiteSão Pauloטרם מגייס

Bulgaria

Bulgaria
מתקןעירמדינה או אזורמצב
Research SiteMontanaטרם מגייס
Research SitePlevenטרם מגייס
Research SitePlovdivמגייס
Research SiteSofiaמגייס
Research SiteSofiaמגייס
Research SiteSofiaמגייס
Research SiteVarnaטרם מגייס
Research SiteYambolמגייס

Canada

Canada
מתקןעירמדינה או אזורמצב
Research SiteBramptonOntarioמגייס
Research SiteCalgaryAlbertaמגייס
Research SiteGuelphOntarioמגייס
Research SiteHamiltonOntarioמגייס
Research SiteMississaugaOntarioמגייס
Research SiteMonctonNew Brunswickמגייס
Research SiteMontrealQuebecמגייס
Research SiteNew WestminsterBritish Columbiaמגייס
Research SiteNorth YorkOntarioמגייס
Research SiteQuébecQuebecמגייס
Research SiteQuébecQuebecמגייס
Research SiteSaint-Charles-BorroméeQuebecמגייס
Research SiteScarborough VillageOntarioמגייס
Research SiteSherbrookeQuebecמגייס
Research SiteStoney CreekOntarioמגייס
Research SiteStouffvilleOntarioמגייס
Research SiteSurreyBritish Columbiaבוטל

170 אתרים נוספים מצוינים ברשומת המרשם.

מסמכי המחקר

לא צורפו מסמכים ברשומת מרשם זו.

שינויים לאורך זמן

  1. 30 באוקטובר 2026

    אתר נוסף

    8 sites added (220 total)

    212220